Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,189 across all filing types
Latest filing 2025-05-15 Capital/Financing Update
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Demerger
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (NSE and BSE) regarding a corporate restructuring event, specifically a demerger of a business division from a wholly owned subsidiary (Arco Lab) into another subsidiary (Pivot Path). It references compliance with SEBI Listing Regulations and provides detailed information about the scheme of arrangement, including the rationale, shareholding changes, and consideration for the demerger. The document is an announcement of a corporate action related to restructuring and capital changes, not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but rather regulatory disclosure about a capital structure change. Therefore, the most appropriate classification is "Capital/Financing Update (CAP)" as it updates on a significant corporate restructuring affecting the company's capital and subsidiaries.
2025-05-15 English
General Updates
Regulatory Filings
2025-05-15 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing about a scheduled earnings call to discuss the audited financial results for the quarter and financial year ended March 31, 2025. It does not contain any financial data or results itself, but rather announces the timing and details of the call. The document length is only 1537 characters, which is quite short and fits the pattern of an announcement rather than a full report or transcript. Therefore, it is not an Earnings Release (ER) or Call Transcript (CT), but rather a Regulatory Filing (RNS) as a general announcement about the earnings call.
2025-05-15 English
Board Meeting — Financial Results/Dividend
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying about a scheduled Board Meeting on May 22, 2025. The agenda includes consideration and approval of audited financial results for the quarter and financial year ended March 31, 2025, and recommendation of a final dividend. It also mentions the closure of the trading window as per insider trading regulations. The document does not contain the financial results themselves but is an announcement of the upcoming board meeting where these results will be approved. The document length is short (1956 characters) and it serves as an intimation or notice rather than a report. Therefore, it is best classified as a Board/Management Information (MANG) filing, which covers announcements of board meetings and related management information.
2025-05-15 English
General Updates
Board/Management Information Classification · 100% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding changes in Senior Management Personnel (SMP) at Strides Pharma Science Limited. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including management changes. The content details appointments and cessations of senior management roles, including names, dates, and brief profiles. There is no financial data, earnings information, or report publication mentioned. The document is clearly an announcement of management changes rather than a full management report or annual report. Therefore, it fits the category of Board/Management Information (MANG). The document length is about 4869 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2025-05-10 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the USFDA approval of Celecoxib Capsules by Strides Pharma Science Limited. It is addressed to stock exchanges and includes details about the product, its market, and company information. There are no financial statements, regulatory certifications, or detailed financial data. The document is relatively short (4301 characters) and serves as a public announcement of a corporate event rather than a financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2025-04-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.